Chinese companies and the UPC: from enforcement targets to strategic users

​
August 13, 2026

The Unified Patent Court (UPC) recently published its 2025 Annual Report, offering a useful snapshot of the court’s development during its second full year of operation. Interestingly, the report highlights the growing prominence of Chinese parties in UPC litigation.

Among infringement actions, China ranks third by claimant origin following Germany and the United States, and fourth by defendant nationality following Germany, The Netherlands and France, underscoring the increasing importance of Chinese companies within the UPC system.

The annual report, however, does not provide a detailed analysis of Chinese participation in patent infringement proceedings. To address that gap, this article undertakes an independent review of all patent infringement actions filed before the UPC Court of First Instance during 2025.

Using the UPC's public case search tool, each infringement action was reviewed individually to identify cases involving at least one Chinese party and to record the relevant technology sector, procedural venue and party position.

The review identified 253 infringement actions recorded in the UPC public case search tool for 2025, of which 97 involved at least one Chinese party.

Chinese parties therefore appeared in approximately 38% of the visible infringement docket.

Chinese-party share of the 2025 UPC infringement docket
0 50 100 150 200 250 Chinese party 97 cases · 38% No Chinese party 156 cases · 62%

The figures confirm that Chinese companies are now among the most frequent participants in UPC litigation. More importantly, they suggest that Chinese companies are transitioning from being primarily enforcement targets to becoming increasingly sophisticated users of the system.

Chinese companies predominantly defendants

The most immediate observation is that Chinese companies continue to be on there receiving end of infringement litigation more often than they act as claimants. Among the 97 cases involving Chinese parties, 84 involved at least one Chinese defendant. Twenty involved a Chinese claimant, including seven disputes in which both claimant and defendant were Chinese entities.

How Chinese parties appeared across the 97 cases
0 20 40 60 80 Defendant only 77 cases Claimant only 13 cases Both Chinese 7 cases

Many of the defendants operate in sectors characterised by intensive patent licensing and enforcement activity, particularly telecommunications, consumer electronics and connected devices.

The data also reveal repeated enforcement campaigns against a relatively small group of companies, including Xiaomi, Transsion, Huawei, OPPO, vivo, BYD, TCL and Hisense. This pattern is consistent with broader global trends in which major operating companies and licensing entities pursue portfolio-based litigation strategies against significant market participants.

Repeat Chinese defendants named in the 2025 UPC docket
Xiaomi
Transsion
Huawei
OPPO
vivo
BYD
TCL
Hisense

For rightsholders, the UPC's ability to deliver remedies covering multiple European jurisdictions through a single action makes it an attractive forum for such campaigns.

For Chinese companies with substantial European operations, the UPC has therefore become a significant litigation risk requiring strategic attention rather than merely reactive defence.

Telecoms remains the centre of gravity

The technology distribution of the cases is equally revealing. Telecommunications and standards-related disputes accounted for the largest share of the docket. Many involved standard essential patents, codec technologies and licensing programmes associated with mobile communications and connected devices.

The UPC offers SEP owners a potentially powerful enforcement mechanism, while implementers face the prospect of pan-European injunctions and damages claims. Unsurprisingly, the court is increasingly becoming part of the global forum competition surrounding SEP disputes.

At the same time, Chinese-party litigation before the UPC is no longer confined to telecommunications.

Significant numbers of cases arose in manufacturing, consumer electronics, chemicals, semiconductors, medical devices, batteries and solar technologies. Particularly notable is the growing presence of disputes involving energy-transition technologies and advanced manufacturing.

The diversification of technologies appearing before the court suggests that the UPC is becoming relevant to a much broader range of Chinese businesses, not only those operating in traditional SEP-heavy sectors.

Germany remains the primary battleground

Venue selection continues to reflect familiar European patent-litigation dynamics. Munich emerged as the leading UPC division for disputes involving Chinese parties, with Mannheim and Düsseldorf also handling substantial numbers of cases. Together, the German local divisions accounted for the overwhelming majority of the litigation.

This concentration reflects the long-standing experience of the German patent judiciary, the commercial significance of the German market and litigants’willingness to build on enforcement strategies developed before the UPC’s creation.

An equally notable feature of the dataset is that Chinese claimants overwhelmingly chose German divisions when enforcing their own patents.

This suggests that Chinese patentees have rapidly adopted the same forum-selection preferences as established European and US litigants, viewing Munich and Mannheim as the UPC's most influential venues for technology disputes.

Where Chinese-party UPC disputes are heard
Munich
Mannheim &
Düsseldorf
The Hague
Caseload of Chinese-party disputes
Leading
Major
Rising
Chosen by Chinese claimants?
Preferred
Preferred
Rarely

The Hague division also saw increasing involvement of Chinese parties, but Chinese claimants rarely selected it as their preferred venue. Instead, Chinese companies appearing before that division were generally defendants responding to actions brought by others. For in-house counsel and patent owners, the data reinforce the importance of Germany as the central venue for UPC enforcement strategies.

The rise of Chinese claimants

Perhaps the most significant development is the growing number of Chinese companies using the UPC offensively. Twenty of the 97 cases involving Chinese parties were initiated by Chinese claimants. Although Chinese entities remain defendants more often than claimants, the emergence of a meaningful claimant cohort is itself noteworthy.

The data suggest that leading Chinese patent owners increasingly view the UPC as a practical mechanism for enforcing patent rights across Europe.

Companies such as Huawei and Yangtze Memory Technologies are no longer merely defending themselves against foreign rightsholders; they are actively leveraging the UPC to support broader commercial and licensing objectives.

Perhaps the clearest indicator of the UPC’s maturation is the emergence of Chinese-versus-Chinese disputes. Seven of the 20 cases brought by Chinese claimants involved Chinese defendants, spanning telecommunications, electronics, manufacturing and solar technologies.

Historically, many disputes between Chinese companies with international operations might have been litigated primarily before Chinese courts. Their appearance before the UPC suggests that parties increasingly regard the court as a strategically important forum for resolving global competitive conflicts

What the data suggest for 2026 and beyond

The findings point to a broader structural shift in the role of Chinese companies within the international patent system.

First, Chinese businesses are becoming an indispensable part of the UPC ecosystem. Their participation is no longer limited to isolated disputes involving a handful of technology companies.

Second, the court is increasingly being used as a strategic enforcement tool by sophisticated Chinese patent owners seeking Europe-wide remedies.

Third, the expansion of litigation into sectors such as semiconductors, medical devices, batteries and renewable-energy technologies suggests that Chinese involvement in UPC proceedings will continue to diversify beyond telecommunications and SEPs.

For patent owners, implementers and investors, the implication is clear, understanding Chinese litigation behaviour is becoming an essential component of UPC strategy. The most important question is no longer whether Chinese companies will participate in the UPC system, but how rapidly they will expand their use of it as both defendants and rightsholders.

The evidence from the 2025 docket suggests that this transition is already underway.

Chinese companies are no longer participating in the UPC primarily because they are being sued there. Increasingly, they are participating because they regard the court as a valuable strategic asset in their own patent enforcement programmes.

‍

Author: Xiaofan Chen - Partner, Chinese Patent Attorney

The Latest Thought Leadership pieces in the Content Hub

No items found.
Stay in the Know

The Patent Strategist

Get expert insights and the top patent stories delivered straight to your inbox.

Heading
This is some text inside of a div block.
This is some text inside of a div block.

Latest Insights

Showing 0 of 100
Is Your AI Conversation Privileged?
08 May 2026
Recent US court decisions have, for the first time, tested whether conversations with AI tools can be protected by legal privilege. In United States v. Heppner, a court held that documents generated by a defendant using a public AI platform were not protected by attorney‑client privilege, largely because the AI was not used within a lawyer‑directed relationship and the platform’s terms allowed data retention and disclosure. By contrast, in Warner v. Gilbarco, another court found that AI‑assisted materials created by a self‑represented litigant were protected under the work‑product doctrine, which has a more forgiving standard for waiver.
#
Consulting
​
The evolution of nucleic acid sequencing and what it means for Genomics and IP
27 April 2026
This article outlines the evolution of nucleic acid sequencing, from early Sanger methods to next‑generation and long‑read technologies. The journey from deciphering individual DNA strands to sequencing entire genomes in hours represents one of biotechnology's most impressive transformations. The first human genome, completed through the Human Genome Project, took around 13 years to sequence and cost billions of dollars, whereas modern sequencing methods can now deliver a genome in hours for a few hundred dollars. For those interested in patents and life sciences, understanding the technical evolution of sequencing methods offers insights into how fundamental scientific advances translate into valuable patent portfolios.
#
Consulting
​
World IP Day: The big ideas shaping IP's fastest-moving fields
24 April 2026
For World IP Day, we asked experts of EIP’s five growth areas: Uniphy, Ampliphy, Stratiphy, Codiphy and Quantiphy, to share a quick insight on innovation, IP trends, and what excites them about the future. Each responded to a single, focused question reflecting the role their team plays across EIP.
#
Consulting
​
Meet the EIP team heading to INTA 2026 in London
23 April 2026
INTA's Annual Meeting is coming to London. From 2–6 May 2026, the ExCeL will host more than 10,000 trade mark and IP professionals from over 100 jurisdictions — five days of sessions, side events, and the kind of corridor conversations that turn into lasting working relationships.
#
Litigation
​
Antibody Patent Protection in Europe and the US: Navigating EPO and USPTO Differences
16 April 2026
This article explores the complexities of patenting antibody therapies, focusing on the differing requirements and practices of the European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO). It highlights how the scope of claims, inventiveness standards, and supporting data requirements vary between jurisdictions, and explains why a tailored IP strategy is essential for innovators especially SMEs seeking protection in both Europe and the US. The article also outlines how EIP’s transatlantic teams collaborate to optimise patent applications for success in these key markets.
#
Patenting
​
Why competitor patent monitoring is critical to your drug development strategy
15 April 2026
This article explains why competitor IP monitoring is a critical part of an effective drug development strategy. By tracking competitor patent activity, companies can assess freedom to operate, identify risks and opportunities early, and make informed decisions on patent filings, licensing, and investment readiness. Ongoing monitoring also supports FTO analysis, third‑party observations, oppositions, and litigation strategy, helping life sciences businesses protect value and reduce risk throughout development.
#
Consulting
​
Biopharma Strategy in 2026: Lessons from 2025 on AI, M&A and the UPC
13 April 2026
This article looks back on a selection of key trends in the (bio)pharma industry in 2025 and looks ahead to how these may continue to develop into 2026.
#
Consulting
​
Thinking about IP from day one: strategic considerations for deep tech startups
08 April 2026
For deep tech startups, intellectual property decisions often come too late or cost too much too soon. This article explores why IP strategy should be considered from day one, even if formal protection comes later. It outlines how founders can decide what to patent, when trade secrets may be more appropriate, and how detectability, enforceability and cost should shape early choices. With a focus on practicality and commercial alignment, it also looks at how newer, AI‑assisted approaches can help startups take a more cost‑effective and flexible approach to building meaningful IP protection.
#
Consulting
​
National offices report increases in national patent applications throughout Europe: Is the EPO no longer “killing” the national offices?
27 March 2026
National patent offices across Europe have reported a marked increase in patent filings in 2025, breaking with a long‑standing downward trend. Data from Germany, France, Italy, Sweden, Austria, Spain and Norway point to growing activity driven by digital technologies, electrification and increased university participation. At the same time, offices report a rise in self‑drafted and AI‑assisted applications, which may lower barriers to entry but also raise concerns about application quality and examination efficiency.
#
Patenting
​
Make your bio(pharma) IP investment ready
22 March 2026
This recap of our LinkedIn Live series focuses on helping (bio)pharma businesses make their IP investment‑ready. Across three sessions, experts will discuss building resilient IP portfolios, making strategic IP decisions ahead of funding rounds, and what the evolving 2026 (bio)pharma landscape means for long‑term IP strategy.
#
Patenting
​
Are professional guidelines making Patent Attorneys too cautious on AI?
19 February 2026
As AI use accelerates in patent practice, many European patent attorneys remain cautious due to professional AI guidelines from the epi. This article argues those guidelines are not a barrier, but a baseline for responsible use.
#
Patenting
​
Provisional Agreement Reached on the EU Pharma Package: Takeaways for Pharmaceutical Companies
17 February 2026
The EU’s new Pharma Package will overhaul regulatory exclusivity, orphan drug incentives, antimicrobial innovation, and generic entry pathways, reducing standard protection periods while introducing new rewards like transferable exclusivity vouchers.
#
Patenting
​
Beyond CRISPR: Precision to Platform
23 January 2026
Gene editing is entering a new phase, moving beyond CRISPR-Cas9’s breakthrough but costly, bespoke therapies toward more precise and scalable platforms. While CRISPR-based treatments like Casgevy have proven clinical success, they remain expensive and entangled in ongoing patent disputes over foundational IP. Next-generation tools such as base editing and prime editing avoid double-strand DNA breaks, enabling more accurate corrections and broader therapeutic potential. The field’s focus is now shifting to disease-agnostic platforms that can be adapted across many conditions, improving access and efficiency.
#
Patenting
​
Confidentiality at the UPC: What litigants need to know
21 January 2026
This article explains how the Unified Patent Court approaches confidentiality in litigation, outlining the procedures for restricting access to sensitive information, how confidentiality clubs are formed, and when hearings may be held in private. It highlights key case law shaping these rules, the balance between fair trial rights and protection of commercial data, and the penalties for breaches. Practical guidance is provided to help parties navigate applications, manage confidential documents, and understand what to expect throughout UPC proceedings.
#
Litigation
​
EPO fees are going up in April 2026: Plan ahead now
19 January 2026
The European Patent Office will introduce a fee increase of roughly 5% from 1 April 2026, affecting search, examination, designation and renewal fees. Filing, excess page, opposition and appeal fees remain unchanged. Some costs—such as renewal fees—can be paid up to three months early, allowing applicants to secure the current lower rates. EIP recommends reviewing your portfolio ahead of the deadline.
#
Patenting
​